Targeting the Calcineurin Pathway Enhances Ergosterol Biosynthesis Inhibitors against \textit{Trichophyton mentagrophytes} In Vitro and in a Human Skin Infection Model\textsuperscript{v}

Chiatou Onyewu,\textsuperscript{3} Emily Eads,\textsuperscript{2} Wiley A. Schell,\textsuperscript{2} John R. Perfect,\textsuperscript{2} Yehuda Ullmann,\textsuperscript{4} Gil Kaufman,\textsuperscript{5} Benjamin A. Horwitz,\textsuperscript{6} Isreala Berdicevsky,\textsuperscript{5} and Joseph Heitman\textsuperscript{1,2,3,}\textsuperscript{*}

\textsuperscript{1}Departments of Molecular Genetics and Microbiology, \textsuperscript{2}Medicine, and \textsuperscript{3}Pharmacology and Cancer Biology, \textsuperscript{4}Duke University Medical Center, Durham, North Carolina 27710; Department of Plastic Surgery, \textsuperscript{5}Rambam Medical Center, Haifa, Israel; and \textsuperscript{6}Faculty of Medicine, Molecular Microbiology, Technion—Israel Institute of Technology, Haifa, Israel

Received 11 April 2007/Returned for modification 24 May 2007/Accepted 20 July 2007

Fluconazole-FK506 or fluconazole-cyclosporine drug combinations were tested in an ex vivo \textit{Trichophyton mentagrophytes} human skin infection model. Conidia colonization was monitored by scanning electron microscopy over a 7-day treatment period. The fluconazole-FK506 combination demonstrated the most obvious advantage over single-drug therapy by clearing conidia and protecting skin from damage at low drug concentrations.

Dermatophyte fungal pathogens cause substantial morbidity in otherwise healthy individuals (15). \textit{Trichophyton} species cause ~70% of all dermatophyte infections (16). Terbinafine and fluconazole are ergosterol biosynthesis inhibitors with antifungal activity against \textit{Trichophyton} species (1, 4, 5), but azoles are used less frequently than terbinafine for management (8). The calcineurin inhibitors cyclosporine A (CsA) and FK506 are synergistic with ergosterol biosynthesis inhibitors against \textit{Candida albicans} (2, 9, 10, 12, 13). We hypothesize that this drug synergy could extend to \textit{Trichophyton mentagrophytes}. We determined MICs and tested the therapeutic potential of proposed drug combinations in an ex vivo human skin infection model (3).

\textit{T. mentagrophytes} strains were grown on potato dextrose agar (30°C, 7 days). Conidia were diluted to 10\textsuperscript{7} CFU/ml in liquid RPMI 1640 (Gibco) buffered to pH 7 with 0.165 M morpholinepropanesulfonic acid and NaOH. In vitro susceptibility assays were performed according to a modified Clinical and Laboratory Standards Institute (CLSI) M38-A protocol. Each drug concentration was prepared at 100 fold, and 0.9 ml of inoculum was added to 0.1 ml of 10 fold, and 0.9 ml of inoculum was added to 0.1 ml of 10 fold drug solution. Drugs were dissolved in 100% dimethyl sulfoxide or ethanol and provided by LC Biolabs, Novartis, and Duke Pharmacy. Drug concentrations were 0.125 μg/ml to 64 μg/ml (CsA and fluconazole), 0.03125 μg/ml to 16 μg/ml (FK506), and 0.004 μg/ml to 2 μg/ml (terbinafine). Both strains exhibited moderate fluconazole sensitivity and potent terbinafine susceptibility (Table 1).

Checkerboard synergy assays with drug concentrations from 0.125 to 8 μg/ml (CsA) and 0.5 to 16 μg/ml (fluconazole) or 0.064 to 4 μg/ml (FK506) and 0.5 to 16 μg/ml (fluconazole) were performed. Terbinafine was excluded due to potency (Table 1). The fractional inhibitory concentration index (ΣFIC) was calculated, and values of ΣFIC < 0.5 revealed synergy, those of ΣFIC > 1 indicated no interaction, and those of ΣFIC > 4 were antagonistic (11). The fluconazole-FK506 combination was synergistic against strain DUMC112.02 (ΣFIC = 0.28). The fluconazole-CsA combination demonstrated synergy against both strains, decreasing MICs by 4- to 32-fold (Table 2). These drug combinations were tested against strain DUMC160.03 in a skin infection model.

Excess full-thickness (0.5 to 1 cm diameter) skin sections from plastic surgery procedures were maintained in sterile skin graft fluid at pH 6.4 for 2 to 3 weeks (3, 14). Samples were inoculated with $1 \times 10^7$ to $5 \times 10^7$ conidia/ml, incubated at 30°C, and monitored by digital scanning electron microscopy; images represent at least five replicates from two independent experiments (3, 6, 7). Drugs were applied 30 minutes after inoculation and then every 2 days. By days 1, 3, and 7 postinfection (p.i.), each sample received one, two, or four treatments, respectively. No agent was deleterious to the skin after 7 days (Fig. 1A). \textit{T. mentagrophytes} rapidly colonized untreated skin, and 1 day after inoculation, hyphae were visible (Fig. 1B). After 3 days, skin appeared damaged with abundant hyphae that further increased by day 7 p.i. (Fig. 1B).

\begin{table}[h]
\centering
\caption{MICs of drugs for \textit{T. mentagrophytes} strains}
\begin{tabular}{lllll}
\hline
Strain\textsuperscript{a} & Ca & FK506 & FLC & TRB \\
\hline
DUMC112.02 & 2 & 1 & 8–16 & 0.004 \\
DUMC160.03 & 1 & 1 & 8–16 & 0.0312 \\
\hline
\end{tabular}
\textsuperscript{a} Strains were from the Duke University Medical Center stock collection. \\
\textsuperscript{b} FLC, fluconazole; TRB, terbinafine. \\
\textsuperscript{c} The lowest MIC (8 μg/ml) was used for ex vivo studies.
\end{table}
Single-dose fluconazole at 2× MIC caused minimal growth inhibition (Fig. 2). Damaged skin samples with prominent conidia were observed on day 3 (Fig. 2). By day 7, hyphae were rare and skin sections appeared normal (Fig. 2). At 2× MIC of terbinafine, germinating conidia and damaged hyphae were visible on day 1 p.i. and rare by day 3 p.i. and skin appeared normal on day 7 p.i. (Fig. 3). These findings support the in vitro assays where terbinafine was more potent than fluconazole (Table 1). At 2× MIC, FK506- and/or CsA-treated samples resembled the untreated controls (compare Fig. 1B and 2).

Fluconazole or terbinafine was combined with each calcineurin inhibitor in ex vivo drug studies. For each drug, MICs or fractional MICs were applied to skin (Table 1). The fluconazole (0.25× MIC)-FK506 (0.5× MIC) combination had little effect on hyphal growth after one dose (Fig. 3A). However, by day 3 p.i., skin appeared normal with no hyphae observed (Fig. 3A). This differed from skin receiving 2× MIC fluconazole alone, which still appeared damaged on day 3 p.i., with hyphae present on day 7 p.i. (Fig. 2). The fluconazole-CsA (1× MIC each) combination resulted in hyphal collapse on day 3 p.i. (Fig. 3A). Hyphae cleared by day 7 p.i., and skin appeared normal (Fig. 3A). Compared to single-drug therapy, the fluconazole-CsA combination achieved an effective dose when the MIC was reduced 50% (Fig. 2).

The terbinafine-FK506 (1× MIC each) combination protected skin from damage; in most fields, no adhering hyphae were observed from days 1 to 7 p.i. (Fig. 3B). These samples resembled those receiving 2× MIC terbinafine monotherapy (Fig. 2). Similarly, no hyphae were observed 7 days after terbinafine-CsA (1× MIC each) treatment (Fig. 3).

As anticipated from the in vitro studies, fluconazole and terbinafine were effective in inhibiting T. mentagrophytes colonization (Fig. 2). We were unable to evaluate positive interactions with terbinafine and CsA and/or FK506 since T. mentagrophytes was highly sensitive to terbinafine alone. The fluconazole-FK506 combination exhibited synergism against DUMC112.02, while the fluconazole-CsA combination was synergistic against DUMC160.03 (Table 2). However, in the infection model, the fluconazole (0.25× MIC)-FK506 (0.5× MIC) combination cleared hyphae more rapidly than the fluconazole-CsA (1× MIC each) combination did, and both combinations were more effective than fluconazole alone at 2× MIC (compare Fig. 2 and 3). The ability of these agents to eliminate colonizing hyphae more rapidly when combined at lower concentrations was indicative of a positive interaction in this ex vivo model.

The proposed drug combinations have in vivo implications since calcineurin inhibitor anti-inflammatory activity might accelerate symptom resolution. Calcineurin inhibitors alone did not improve disease resolution (Fig. 2), but as adjuncts to topical antifungal therapies, they may facilitate healing by reducing inflammatory mediators at infection sites. Rapidly healing lesions could result in improved patient compliance, de-

---

**TABLE 2. T. mentagrophytes MICs and ΣFICs for combination therapy**

<table>
<thead>
<tr>
<th>Strain</th>
<th>MIC80 (μg/ml)</th>
<th>FLC80-CsA</th>
<th>Combined MIC</th>
<th>ΣFIC80</th>
<th>Combined MIC</th>
<th>ΣFIC80</th>
</tr>
</thead>
<tbody>
<tr>
<td>DUMC112.02</td>
<td>16</td>
<td>2</td>
<td>1</td>
<td>4/0.5</td>
<td>0.5</td>
<td>4.03</td>
</tr>
<tr>
<td>DUMC160.03</td>
<td>16</td>
<td>8</td>
<td>1</td>
<td>0.5/2</td>
<td>0.28</td>
<td>4.03</td>
</tr>
</tbody>
</table>

* a MIC at which 80% of the isolates tested are inhibited.
  b FLC, fluconazole.
  c Shown as MIC of first drug/MIC of second drug, both in micrograms per milliliter.
  d ΣFIC values represent the median values from two or more experiments.

---

**FIG. 1.** Experimental and treatment controls for the ex vivo skin infection model. (A) In the absence of T. mentagrophytes, antifungal agents were applied at 2× MIC to skin samples every 2 days for 7 days with no damage to skin integrity. Scanning electron microscopy images show the skin surface. Samples were fixed following 7 days of treatment. Bars, 5 μm. (B) T. mentagrophytes conidia begin to colonize skin samples at day 1 p.i. and produce a dense collection of hyphae by day 7 p.i. on untreated skin samples. D0, D1, D3, and D7 refer to the number of days p.i.
FIG. 2. The ex vivo dermatophyte skin infection model responds to drug treatment. Skin samples colonized with *T. mentagrophytes* (DUMC160.03) were treated every 2 days (days 0, 2, 4, and 6) with 2× MIC of fluconazole, terbinafine, FK506, or CsA. Samples were fixed at the indicated times. A significant reduction in hyphal colonization and intact skin was observed by day 7 p.i., demonstrating the efficacy of fluconazole or terbinafine. FK506 or CsA treatment did not result in hyphal clearing or improved skin integrity.

FIG. 3. *T. mentagrophytes* is susceptible to drug combinations in the ex vivo infection model. The antifungal activity of fluconazole was enhanced by FK506 or CsA. (A) Fluconazole was more effective by day 3 p.i. when combined with FK506 or CsA (compare with Fig. 2). The accelerated hyphal clearing observed when drugs were combined at lower concentrations was indicative of drug synergy. (B) Samples treated with terbinafine-CsA or terbinafine-FK506 combinations were indistinguishable from those treated with terbinafine alone (Fig. 2). FLC, fluconazole; TRB, terbinafine. Bars, 5 μm (unless otherwise indicated).
creased morbidity, and avoidance of adverse effects from some oral therapies. However, these immunosuppressants could also negatively affect local immune processes. This dermatophyte infection model simulates human infection and allows evaluation of host-pathogen interactions (3). It could facilitate drug studies because skin can be inoculated, treated with multiple drugs, and processed efficiently with implications for understanding pathogenesis and establishing new treatment. Skin specimens from different patient populations can be investigated for genetic contributions to drug responses and disease susceptibility.

We are grateful to N. Isham and M. A. Ghannoum for strains and advice. This work was supported by RO1 grant NIH/NIAID AI50438, a Howard Hughes Research Training Fellowship to Emily Eads, a Technion V.P.R. Fund grant to Israela Berdicevsky, and a UNCF/Merck Graduate Fellowship to Chiatogu Onyewu.

REFERENCES